Oxford Biomedica inks deal with Juno on LentiVector platform for CAR-T and TCR-T therapeutics

18 March 2020

UK gene and cell therapy company Oxford Biomedica (LSE: OXB) has signed a new licence and clinical supply agreement (LSA) with Juno Therapeutics, a part of Bristol-Myers Squibb (NYSE: BMY), with market reacting initially sending the firm’s shares 5.6% lower to 377.50 pence, albeit in a market shedding a similar percentage, but recovering to 839.54 pence.

The LSA grants Juno Therapeutics a non-exclusive license to Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programs in oncology and other indications, and additionally puts in place a five-year clinical supply agreement, which may be extended further.

Deal worth a potential $227 million

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK